Exportin-5 SUMOylation promotes hepatocellular carcinoma progression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Abnormal XPO5 expression is linked to various human cancers, acting as an oncoprotein.
• The specific function of XPO5 in hepatocellular carcinoma (HCC) has not been previously investigated.

Purpose of the Study:

• To elucidate the role of XPO5 and its modification in HCC progression.
• To identify the molecular mechanisms by which XPO5 influences HCC cell behavior.

Main Methods:

• Analysis of XPO5 expression in HCC tissues.
• Investigation of XPO5 SUMOylation at K125 by SUMO2.
• Functional assays assessing cell proliferation, migration, and invasion.
• Studies on pre-miR-3184 nuclear export and PLCB1 targeting by miR-3184.
• Bioinformatics analysis of PLCB1 expression and patient survival.

Main Results:

• XPO5 is highly expressed in HCC and undergoes SUMOylation by SUMO2 at K125.
• SUMOylated XPO5 enhances MHCC97H cell proliferation, migration, and invasion.
• SUMOylated XPO5 inhibits the nuclear export of pre-miR-3184, leading to PLCB1 upregulation.
• PLCB1 is a common target of miR-3184-5p and miR-3184-3p, and its overexpression rescues the phenotype induced by these miRNAs.
• High PLCB1 expression correlates with poor HCC patient survival.

Conclusions:

• SUMOylated XPO5 promotes HCC progression by regulating miR-3184 nuclear-cytoplasmic transport.
• This mechanism leads to the upregulation of PLCB1, contributing to increased proliferation, migration, and invasion in HCC.
• Targeting XPO5 SUMOylation or PLCB1 may offer therapeutic strategies for HCC.